CN105194655A - Therapeutic method of neonatal bacterial infective encephalitis - Google Patents
Therapeutic method of neonatal bacterial infective encephalitis Download PDFInfo
- Publication number
- CN105194655A CN105194655A CN201510682494.0A CN201510682494A CN105194655A CN 105194655 A CN105194655 A CN 105194655A CN 201510682494 A CN201510682494 A CN 201510682494A CN 105194655 A CN105194655 A CN 105194655A
- Authority
- CN
- China
- Prior art keywords
- encephalitis
- therapeutic method
- cells
- present
- neonates
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010014599 encephalitis Diseases 0.000 title claims abstract description 21
- 238000002560 therapeutic procedure Methods 0.000 title claims abstract description 15
- 230000001580 bacterial effect Effects 0.000 title abstract 3
- 230000001524 infective effect Effects 0.000 title abstract 3
- 102000004889 Interleukin-6 Human genes 0.000 claims abstract description 13
- 108090001005 Interleukin-6 Proteins 0.000 claims abstract description 13
- 229940100601 interleukin-6 Drugs 0.000 claims abstract description 13
- 239000000203 mixture Substances 0.000 claims abstract description 10
- 208000035143 Bacterial infection Diseases 0.000 claims description 18
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 18
- 108010090804 Streptavidin Proteins 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 3
- 229960000723 ampicillin Drugs 0.000 claims description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 abstract description 3
- 102000011767 Acute-Phase Proteins Human genes 0.000 abstract description 2
- 108010062271 Acute-Phase Proteins Proteins 0.000 abstract description 2
- 206010061218 Inflammation Diseases 0.000 abstract description 2
- 230000004071 biological effect Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 abstract description 2
- 230000024245 cell differentiation Effects 0.000 abstract description 2
- 210000004969 inflammatory cell Anatomy 0.000 abstract description 2
- 230000004054 inflammatory process Effects 0.000 abstract description 2
- 230000031146 intracellular signal transduction Effects 0.000 abstract description 2
- 230000000770 proinflammatory effect Effects 0.000 abstract description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 abstract description 2
- 210000004509 vascular smooth muscle cell Anatomy 0.000 abstract description 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- 238000010523 cascade reaction Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 210000002540 macrophage Anatomy 0.000 abstract 1
- 238000001243 protein synthesis Methods 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 230000014616 translation Effects 0.000 abstract 1
- 201000009906 Meningitis Diseases 0.000 description 6
- 206010040047 Sepsis Diseases 0.000 description 3
- 208000013223 septicemia Diseases 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000002418 meninge Anatomy 0.000 description 2
- 206010034754 petechiae Diseases 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 206010004053 Bacterial toxaemia Diseases 0.000 description 1
- 206010009192 Circulatory collapse Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010022773 Intracranial pressure increased Diseases 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 208000003773 Meningism Diseases 0.000 description 1
- 206010027202 Meningitis bacterial Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 208000013222 Toxemia Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 201000009904 bacterial meningitis Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 206010040560 shock Diseases 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention discloses a therapeutic method of neonatal bacterial infective encephalitis. The therapeutic method comprises the step of applying a composition containing at least one type of interleukin 6 (IL-6) to a child suffering from bacterial infective encephalitis. The IL-6 provided by the invention is a pro-inflammatory factor generated by various types of cells in vivo such as mononuclear macrophages, T/B lymphocytes, vascular endothelial cells and smooth muscle cells, is located in a central position in an inflammation cascade reaction, can take various biological effects through an intracellular signal transduction pathway after being bonded with a receptor, and has the functions of resisting infection, stimulating inflammatory cells to grow, promote cell differentiation, and accelerating acute phase protein synthesis.
Description
Technical field
The present invention relates to medical field, be specially a kind of Therapeutic Method of neonates with bacterial infections encephalitis.
Background technology
At present, bacterial meningitis is the infectious disease that central nervous system is serious, is grown up common, and child patient is especially many.Many antibacterials all can cause primary disease, and wherein person caused by meningococcus is maximum, are followed successively by hemophilus influenza, streptococcus pneumoniae, escherichia coli and other Grain-positive bacillus, staphylococcus, Lee department too Seedling, anaerobe etc.
And epidemic cerebrospinal meningitis is the purulent meningitis caused by meningococcus.Pathogenic bacterium invade blood circulation by nasopharynx part, form septicemia, are finally confined to meninges and membrane of spinal cord, form suppurative meninges pathological changes.Cardinal symptom performance has the meningeal irritation signs such as heating, headache, vomiting, skin petechia and stiffness of the neck.Cerebrospinal fluid is suppurative change.The state of an illness of epidemic cerebrospinal meningitis is complicated and changeable, and weight differs, and generally can have three kinds of clinical manifestations, i.e. plain edition, fulminant type and chronic septicemia type.Plain edition accounts for whole patient's about 90%, can be divided into upper respiratory tract infection phase, septicemia phase and meningitis phase three classes by its evolution.Meningitis phase patient Gao Re and lasting toxemia, whole body still has petechia, ecchymosis, but central nervous system disorders shape increases the weight of.Because of increased intracranial pressure patient One's head is splitting, vomiting is frequent, blood pressure can increase and pulse slows down, and often has skin allergy, keeps in dark place, manic and faint from fear.After 1-2 days, patient enters delirium comatose state, can occur breathing or circulatory failure.Evening, hair style meningitis was more common in child.
Summary of the invention
Technical problem solved by the invention is the Therapeutic Method providing a kind of neonates with bacterial infections encephalitis, to solve the shortcoming in above-mentioned background technology.
Technical problem solved by the invention realizes by the following technical solutions: a kind of Therapeutic Method of neonates with bacterial infections encephalitis, comprises and use to the child suffering from bacterial infection encephalitis the compositions comprising at least one interleukin 6 (IL-6).
In the present invention, further, Streptavidin is contained in wherein said compositions.
In the present invention, further, ampicillin is contained in wherein said compositions.
In the present invention, further, wherein said bacterial infection encephalitis is acute.
In the present invention, further, wherein said at least one anti-IL-6 antibodies is for people IL-6.
In the present invention, further, the anti-IL antibody of wherein said at least one is neutrality.
In the present invention, further, wherein said at least one anti-IL-6 antibodies is humanized.
Beneficial effect of the present invention: IL-6 is the Pro-inflammatory mediator produced as mononuclear phagocyte, T, bone-marrow-derived lymphocyte, vascular endothelial cell and smooth muscle cell etc. by various kinds of cell in body, Central Position is in cascade of response of inflammation, after itself and receptors bind, through intracellular signal transduction approach performance various biological effect, there is infection, stimulate inflammatory cell growth, promote the effect that cell differentiation and acceleration acute phase protein synthesize.
Detailed description of the invention
The technological means realized to make the present invention, creation characteristic, reach object and effect is easy to understand, below to set forth the present invention further.
A Therapeutic Method for neonates with bacterial infections encephalitis, comprises and uses to the child suffering from bacterial infection encephalitis the compositions comprising at least one interleukin 6 (IL-6).
In the present invention, further, Streptavidin is contained in wherein said compositions.
In the present invention, further, ampicillin is contained in wherein said compositions.
In the present invention, further, wherein said bacterial infection encephalitis is acute.
In the present invention, further, wherein said at least one anti-IL-6 antibodies is for people IL-6.
In the present invention, further, the anti-IL antibody of wherein said at least one is neutrality.
In the present invention, further, wherein said at least one anti-IL-6 antibodies is humanized.
More than show and describe ultimate principle of the present invention and principal character and advantage of the present invention; the technical staff of the industry should understand; the present invention is not restricted to the described embodiments; what describe in above-described embodiment and description just illustrates principle of the present invention; without departing from the spirit and scope of the present invention; the present invention also has various changes and modifications; these changes and improvements all fall in the claimed scope of the invention, and application claims protection domain is defined by appending claims and equivalent thereof.
Claims (7)
1. a Therapeutic Method for neonates with bacterial infections encephalitis, is characterized in that: comprise and use to the child suffering from bacterial infection encephalitis the compositions comprising at least one interleukin 6 (IL-6).
2. the Therapeutic Method of a kind of neonates with bacterial infections encephalitis of claim 1, is characterized in that: containing Streptavidin in wherein said compositions.
3. the Therapeutic Method of a kind of neonates with bacterial infections encephalitis of claim 1, is characterized in that: containing ampicillin in wherein said compositions.
4. the Therapeutic Method of a kind of neonates with bacterial infections encephalitis of claim 1, is characterized in that: wherein said bacterial infection encephalitis is acute.
5. the Therapeutic Method of a kind of neonates with bacterial infections encephalitis of claim 1, is characterized in that: wherein said at least one anti-IL-6 antibodies is for people IL-6.
6. the Therapeutic Method of a kind of neonates with bacterial infections encephalitis of claim 5, is characterized in that: the anti-IL antibody of wherein said at least one is neutrality.
7. the Therapeutic Method of a kind of neonates with bacterial infections encephalitis of claim 1, is characterized in that: wherein said at least one anti-IL-6 antibodies is humanized.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510682494.0A CN105194655A (en) | 2015-10-21 | 2015-10-21 | Therapeutic method of neonatal bacterial infective encephalitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510682494.0A CN105194655A (en) | 2015-10-21 | 2015-10-21 | Therapeutic method of neonatal bacterial infective encephalitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105194655A true CN105194655A (en) | 2015-12-30 |
Family
ID=54942832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510682494.0A Pending CN105194655A (en) | 2015-10-21 | 2015-10-21 | Therapeutic method of neonatal bacterial infective encephalitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105194655A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103601806A (en) * | 2012-05-23 | 2014-02-26 | 亚根-X公司 | Il-6 binding molecules |
-
2015
- 2015-10-21 CN CN201510682494.0A patent/CN105194655A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103601806A (en) * | 2012-05-23 | 2014-02-26 | 亚根-X公司 | Il-6 binding molecules |
Non-Patent Citations (2)
| Title |
|---|
| 牛俊梅等: "结核性脑膜炎脑脊液中白细胞介素-6水平及临床意义", 《现代预防医学》 * |
| 裘云庆: "婴儿和儿童细菌性脑膜炎患者中白细胞介素-6的活性", 《 国外医学(流行病学传染病学分册)》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chessa et al. | An overview of Staphylococcus epidermidis and Staphylococcus aureus with a focus on developing countries | |
| Wang et al. | Expression of IL-23 and IL-17 and effect of IL-23 on IL-17 production in ankylosing spondylitis | |
| UA124609C2 (en) | INDOLES FOR USE IN INFECTION CAUSED BY INFLUENZA VIRUS | |
| Rainard et al. | Host factors determine the evolution of infection with Staphylococcus aureus to gangrenous mastitis in goats | |
| Kanakadandi et al. | The Austrian syndrome: a case report and review of the literature | |
| McMahon et al. | Murine laminin binds to Histoplasma capsulatum. A possible mechanism of dissemination. | |
| WO2022100125A1 (en) | Novel application of lactobacillus paracasei et-22 in anti-aging and improving innate immunity | |
| Underwood et al. | Innate immunity and the role of defensins in otitis media | |
| EP3322408B1 (en) | Novel formulation for the elimination of cariogenic and opportunistic pathogens within the oral cavity | |
| CN105194655A (en) | Therapeutic method of neonatal bacterial infective encephalitis | |
| Lindhauer et al. | Antibacterial activity of a Tribolium castaneum defensin in an in vitro infection model of Streptococcus pneumoniae | |
| Sullam | Host-pathogen interactions in the development of bacterial endocarditis | |
| Seneviratne | Microbial biofilms: omics biology, antimicrobials and clinical implications | |
| Ghahremanloo et al. | Antifungal effect of silver nanoparticles in acrylic resins | |
| CN107827957B (en) | Anti- clinic multi-drug resistant bacteria small peptide | |
| Peppoloni et al. | The lack of pneumococcal surface protein C (PspC) increases the susceptibility of Streptococcus pneumoniae to the killing by microglia | |
| Negrini et al. | Salivary epithelial cells as model to study immune response against cutaneous pathogens | |
| CN207537632U (en) | A kind of nano-antibacterial viscose fiber yarn | |
| Lipuma et al. | Role of capsule in adherence of Haemophilus influenzae type b to human buccal epithelial cells | |
| CN104293790B (en) | A kind of application of anti-MRSA quorum sensings agr system antisense DNAzymes | |
| WO2021007091A3 (en) | Prebiotic cosmetic compositions and methods for the preparation thereof | |
| Green et al. | The microbiome in chronic inflammatory airway disease: A threatened species | |
| CN204656552U (en) | Can be used for the wide spectrum magnetic bead structure of septic blood cleaning | |
| CN100540047C (en) | Application of TRAP protein in the preparation of medicines for treating Staphylococcus aureus infection | |
| Podgórska et al. | FROM A COMMENSAL TO A PATHOGEN–TWO FACES OFSTAPHYLOCOCCUS EPIDERMIDIS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20151230 |